The FDA approval of an in-house RFFIT lab is a modest positive for Kamada's rabies franchise, potentially improving margins and reducing supply chain risk. Monitor for any future guidance updates or margin improvements in upcoming quarterly reports.
Price Chart
Executive Summary
Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufacturing of KEDRAB and KAMRAB. The lab is expected to improve operational efficiencies and reduce reliance on external testing for its leading rabies franchise, which generated over $70 million in 2025 sales.
Key Facts
- FDA approved Kamada's new in-house RFFIT laboratory for rabies virus neutralization testing.
- The lab is located at Kamada's Beit Kama, Israel plant and is one of a limited number worldwide capable of such tests.
- The lab was also approved by Health Canada and the Israeli Ministry of Health prior to FDA approval.
- In 2025, Kamada's sales of KEDRAB and KAMRAB totaled over $70 million.
- The lab supports manufacturing of KEDRAB and KAMRAB from plasma collection to final product release.
Financial Impact
Operational efficiency gains on a franchise generating over $70 million in annual sales; no specific cost savings or revenue impact quantified.
Risk Factors
- No quantified financial impact from the lab approval; benefits may be gradual.
- Operational execution risk in transitioning testing from external to in-house capabilities.
- Geopolitical risk from the lab's location in Israel.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063140 |
| Document: ea0292886-6k_kamada.htm | 0001213900-26-063140 |
| Document: 0001213900-26-063140-index-headers.html | 0001213900-26-063140 |
| Document: 0001213900-26-063140-index.html | 0001213900-26-063140 |
| Document: 0001213900-26-063140.txt | 0001213900-26-063140 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | EFFECT | $8.19 $8.77 | ▲ +7.08% | ▲ +4.52% | $8.20 (+0.12%) |
Sep 10, 2026 22d ago | 6-K | $7.99 $8.67 | ▲ +8.51% | ▲ +9.01% | $8.20 (+2.63%) |
Sep 3, 2026 29d ago | Press Release | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Sep 3, 2026 29d ago | 6-K | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Aug 17, 2026 6w ago | 6-K / PRESS-RELEASE | $7.76 $8.43 | ▲ +8.63% | ▲ +9.82% | $8.20 (+5.67%) |
Aug 12, 2026 7w ago | 6-K | $6.88 $7.89 | ▲ +14.68% | ▲ +15.12% | $8.20 (+19.19%) |
Aug 5, 2026 8w ago | 6-K | $7.14 $7.26 | ▲ +1.68% | ▲ +0.47% | $8.20 (+14.85%) |
Aug 5, 2026 8w ago | 6-K | $7.18 $6.88 | ▼ −4.18% | ▼ −4.53% | $8.20 (+14.21%) |
Jul 20, 2026 10w ago | 6-K | $7.09 $7.06 | ▼ −0.42% | ▲ +0.00% | $8.20 (+15.66%) |
Jul 13, 2026 11w ago | 6-K | $7.17 $7.05 | ▼ −1.67% | ▼ −0.89% | $8.20 (+14.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access